Abt-751 (Not yet branded)
Other Medications
Description
ABT-751 is a novel tubulin-binding agent that belongs to the sulfonamide class of antimitotic compounds. This oral anticancer drug has been evaluated specifically for treatment of metastatic colorectal cancer in patients who have progressed on standard chemotherapy regimens. ABT-751 works by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Mechanism of Action
ABT-751 binds to the colchicine binding site on ?-tubulin, preventing proper microtubule polymerization and destabilizing the microtubule network. This disruption of the cellular cytoskeleton blocks cells in the G2/M phase of the cell cycle, ultimately triggering apoptotic cell death. Unlike other tubulin-targeting agents, ABT-751 may retain activity against tumors that have developed resistance to taxanes or vinca alkaloids due to its distinct binding site.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.